A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment

Cancer type: Lung cancer

Phase: II

Principal Investigator: Fløtten Øystein

Country: NO

Keywords: Norway, Bergen

Status: Completed

Link to